News Archive

T, business, human capital and other stakeholders can now use cloud-based analytics to more effectively attract, acquire, serve and engage customers, Deloitte Digital announced today. Deloitte Digital has created an analytics offering for Wave, the Salesforce Analytics Cloud that is designed to offer greater flexibility than on-premises solutions. Deloitte Digital’s approach to cloud-based analytics is designed to help companies create strategies for success in a new environment. An example of Deloitte Digital’s commitment to Salesforce Analytics Cloud is its Member Connect solution, a health care industry-focused accelerator with an intuitive approach to the customer journey focusing on omni-channel interactions and a holistic view of the customer.

Of the 115 healthcare accelerators in the world, 87 are in the U.S., most of them are geared to digital health and are under two years old. Although many accelerator companies have created jobs and there have been some exits, most have yet to show anything for the investment in them. That’s understandable given the age of the average accelerator and given that it can take seven years before a company can realize a return on capital for investors. But the consensus of a new report published by the California HealthCare Foundation is that we should expect some consolidation soon.

Joel S. Marcus, founder, chairman, and chief executive of Alexandria Real Estate Equities, has focused the real estate investment trust on developing properties for the life sciences industry. While it operates in other biotechnology and medical technology hubs from New York to San Francisco, the Pasadena, Calif., company’s largest cluster of properties is in Greater Boston, where it owns 3.5 million square feet of space in Cambridge’s Kendall Square, along Route 128, and in Boston’s Longwood Medical Area. On a visit to Cambridge, the 67-year-old Marcus spoke with Globe reporter Robert Weisman. Here’s what he found out:

Downtown Partnership of Baltimore Inc. is launching a grant program aimed at getting more tech firms to consider moving downtown.

The nonprofit is offering six $10,000 grants to tech firms willing to give office space a try downtown for at least a year. Firms must locate to within Downtown Partnership’s “management authority area,” a 106-block area that includes the central business district, part of midtown’s west side and the west side of downtown up to Greene Street.

Another incubator is ready to test Y Combinator’s theory that it is possible to get a biotech-related startup off the ground with smaller sums of money than ever before. VC shop SOS Ventures is offering startups working broadly in biology $35,000 in seed funding, mentors and lab space at incubators in San Francisco and Cork, Ireland.

Like Y Combinator, SOS Ventures is casting its net beyond traditional biotech startups to include any company developing products, processes or software that have a basis in biology. Synthetic biology is an area of particular interest for the team behind the incubator–called IndieBio–and was the focus of a 6-startup pilot accelerator SOS Ventures ran in Cork earlier this year. The VC firm is now scaling up its incubator ambitions.

The University Senate made progress on the policies and guidelines that address non-tenure-track faculty — or professional track faculty, as they will soon be addressed, after a proposal passed in the senate yesterday.

The proposal, which passed by a vote of 61–12 with four abstentions, aims to create an overall title for faculty who are not on the tenure track but contribute to the university through teaching, research or service.

As Alexandria Real Estate Equities (NYSE: ARE) marks the 20th anniversary of its founding, the provider of state-of-the-art real estate for the science and technology industries is seeing occupancy, demand and new development all reach record levels.

“It’s an interesting time because we’re seeing the innovation economy doing miraculously well,” said Joel Marcus, founder and CEO of Pasadena, Calif.-based Alexandria.

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

In order to access this content you need to be logged into the site and have an active subscription or trial subscription.  Please login, take a free trial or subscribe in order to continue reading.

For creative writing, Joyce Carol Oates got it right when she advised, “Be daring, take on anything.”

But when you are trying to make a good first impression on you future boss, concision and confidence sets a qualified applicant apart from one who doesn’t sound sure of her own experience.

Swiss drug major Roche (ROG: SIX) has acquired exclusive rights to a primer extension-based target enrichment technology and associated patent applications filled by therapeutic target discovery company AbVitro.

AbVitro and Roche scientists are to collaborate on the development and application of the technology, which will be used to support next-generation sequencing directly from blood or other biological samples, a key advantage for clinical sequencing applications. It will be incorporated into Roche’s sequencing unit research and development pipeline to support the strategy of providing a full next-generation sequencing workflow solution for clinical sequencing.